Patents Assigned to Flamel Technologies
  • Publication number: 20080026070
    Abstract: The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles—AP—particularly protein and peptide active principles, and to the applications, especially therapeutic applications, of these formulations. This formulation comprises an aqueous colloidal suspension of low viscosity based on micrometric particles of a water-soluble, biodegradable, amphiphilic polymer PO carrying hydrophobic groups (GH)— alpha-tocopherol—and ionizable hydrophilic groups (GI)—Glu—that are at least partially ionized, said particles being capable of associating spontaneously and non-covalently with an AP, at pH=7.0, under isotonic conditions, and having a size of between 0.5 and 100 ?m.
    Type: Application
    Filed: June 11, 2007
    Publication date: January 31, 2008
    Applicant: Flamel Technologies, Inc.
    Inventor: Cecile Bonnet-Gonnet
  • Publication number: 20080026056
    Abstract: The invention relates to oral antibiotic drugs. The object of the invention is to limit or even stop the increase in antibiotic resistance without sacrificing the requirements of (a) increased efficacy of oral antibiotics, particularly for pediatric applications, (b) tolerance, (c) broad spectra of activity, and (d) good patient compliance.
    Type: Application
    Filed: May 25, 2005
    Publication date: January 31, 2008
    Applicant: Flamel Technologies
    Inventors: Florence Guimberteau, Catherine Castan, Remi Meyrueix, Gerard Soula
  • Publication number: 20080015332
    Abstract: The invention concerns a suspension of biocompatible particles for carrying active principles. Said carrier particles are based on a double-block hydrophilic neutral polyaminoacid/hydrophobic neutral polyaminoacid copolymer. Said hydrophilic neutral polyaminoacid/hydrophobic neutral polyaminoacid particles are capable of combining in colloidal suspension in non-dissolved state, at least an active principle and of releasing same, in particular in vivo, in prolonged and/or delayed delivery. The invention also concerns a powdery solid from which are derived the carrier particles and the preparation of said solid and of said suspension of active principle based on hydrophilic neutral polyaminoacids/hydrophobic neutral polyaminoacids. Said carrier particles form spontaneously and in the absence of surfactants or organic solvents, stable aqueous suspensions.
    Type: Application
    Filed: July 24, 2007
    Publication date: January 17, 2008
    Applicant: Flamel Technologies, Inc.
    Inventors: Nathan Bryson, Gerard Soula
  • Publication number: 20080008659
    Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.
    Type: Application
    Filed: January 10, 2007
    Publication date: January 10, 2008
    Applicant: Flamel Technologies
    Inventors: Florence Guimberteau, Frederic Dargelas, Gerard Soula, Remi Soula
  • Publication number: 20070269517
    Abstract: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of an interferon (IFN) (and one or more other possible active principles), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of interferon(s) (and one or more other possible active principles) that makes it possible, after parenteral injection, significantly to increase the in vivo release time of the interferons while at the same time reducing the plasma concentration peak of this IFN, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance.
    Type: Application
    Filed: November 19, 2004
    Publication date: November 22, 2007
    Applicant: Flamel Technologies, Inc.
    Inventors: Gauthier Pouliquen, Remi Meyrueix, Olivier Soula
  • Publication number: 20070264346
    Abstract: The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. The invention relates to an oral form comprising microparticles of the reservoir type for the modified release of at least one active principle (AP), characterized in that it is resistant to immediate dumping of the dose of AP in the presence of alcohol. In particular, the oral form according to the invention is characterized in that the time taken to release 50% of the AP in an alcoholic solution is not reduced more than 3-fold relative to the time taken to release 50% of the AP in an alcohol-free aqueous medium.
    Type: Application
    Filed: February 16, 2007
    Publication date: November 15, 2007
    Applicant: Flamel Technologies
    Inventors: Florence Guimberteau, Frederic Dargelas
  • Publication number: 20070264326
    Abstract: The field of the present invention is that of solid microparticulate analgesic oral medicines. The invention is that of providing novel analgesic medicines which allow at the same time the prevention of misuse and of addiction to certain analgesics, and/or the control of variability in the plasma concentration and/or the facilitation of oral administration; and/or the combination of analgesics with one another and/or with one or more active ingredients in the same oral form. The medicine according to the invention comprises (i) anti-misuse means and a plurality of microcapsules with modified release of analgesic(s), having a mean diameter of between 50 and 600 ?m, (ii) at least 1000 microcapsules per dose; it being possible for this medicine to be administered once or twice a day for analgesic purposes.
    Type: Application
    Filed: January 3, 2007
    Publication date: November 15, 2007
    Applicant: Flamel Technologies
    Inventors: Florence Guimberteau, Gerard Soula
  • Publication number: 20070248686
    Abstract: A suspension of vector particles (PV) based on polyamino acids and have a mean hydrodynamic diameter between 30 and 120 nm, and an insulin load factor of from 5 to 25% of associated insulin volume relative to the polyamino acid volume forming the vector particles. The polyamino acids are double-block polymers containing hydrophilic and hydrophobic monomers. The suspension may be prepared by copolymerizing N-carboxy anhydrides of hydrophobic monomers and precursors of hydrophilic monomers, in the presence of N-methyl pyrrolidone and methanol. The copolymer is optionally neutralized, subjected to dialysis, concentrated and water is eliminated to produce a solid powder, which can be suspended in a liquid to produce the colloidal suspension. Active principles such as insulin or vaccines are associated with the carrier particles to prepare special pharmaceutical products.
    Type: Application
    Filed: April 12, 2007
    Publication date: October 25, 2007
    Applicant: Flamel Technologies
    Inventors: Franck Touraud, Nathan Bryson
  • Publication number: 20070224129
    Abstract: The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.
    Type: Application
    Filed: May 24, 2006
    Publication date: September 27, 2007
    Applicant: Flamel Technologies, Inc.
    Inventors: Florence Guimberteau, Frederic Dargelas
  • Patent number: 7270832
    Abstract: A suspension of biocompatible particles based on a double-block hydrophilic neutral polyminoacid/hydrophobic neutral polyaminoacid copolymer and suitable for carrying active principles. The carrier particles can combine in colloidal suspension in a non-dissolved state with an active principle and release same, particularly in vivo, in prolonged and/or delayed delivery. The carrier particles may be derived from a powdery solid, and spontaneously form stable aqueous suspensions in the absence of surfactants or organic solvents. The invention also concerns the carrier particles in dry form, the method of preparing them, and pharmaceutical compositions (in dry form or suspension) which include the carrier particles associated with an active principle.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: September 18, 2007
    Assignee: Flamel Technologies, Inc.
    Inventors: Nathan Bryson, Gérard Soula
  • Publication number: 20070207214
    Abstract: The invention concerns a galenic system with prolonged/controlled release of the medicinal and/or nutritional active principle, for oral administration. The aim is to provide a system enabling to obtain with one single tolerable and acceptable dose of active principle, efficient therapeutic protection over 24 hours (increasing the bioabsorption time without affecting bioavailability).
    Type: Application
    Filed: March 21, 2007
    Publication date: September 6, 2007
    Applicant: Flamel Technologies
    Inventors: Catherine Castan, Valerie Legrand, Remi Meyrueix, Gerard Soula
  • Publication number: 20070202049
    Abstract: An oral solid dosage form containing one or several active principle(s) having analgesic properties, the composition of said dosage form being such that it prevents the misuse of said dosage form through the liquid extraction of the active principle(s) contained therein, using commonly available solvents. Said oral solid dosage form containing at least one salt of at least one analgesic active principle, and an anti-misuse system comprising at least one quenching agent, said quenching agent being suitable for inducing complexation of said analgesic active principle salt when the analgesic active principle salt is improperly extracted, notably by a drug abuser, in vitro in solution from said oral solid dosage form.
    Type: Application
    Filed: May 24, 2006
    Publication date: August 30, 2007
    Applicant: Flamel Technologies, Inc.
    Inventors: Florence Guimberteau, Frederic Dargelas, Gerard Soula, Remi Soula
  • Publication number: 20070196497
    Abstract: The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of active principle(s), particularly protein active principle(s), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of active principle(s) that makes it possible, after parenteral injection, to increase significantly the in vivo release time of a therapeutic protein while at the same time reducing the plasma concentration peak of the active protein, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance.
    Type: Application
    Filed: November 19, 2004
    Publication date: August 23, 2007
    Applicant: Flamel Technologies, Inc.
    Inventors: Gauthier Pouliquen, Olivier Soula, Remi Meyrueix, Florence Nicolas
  • Publication number: 20070178126
    Abstract: The invention relates to novel biodegradable polyamino acid based materials which can be used for the vectorization of (an) active substance(s) (PA). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The present invention which primarily relates to polyamino acids comprising aspartic units and/or glutamic unites some of which bearing at least one graft, characterized in that at least one of said grafts is joined to an aspartic or glutamic unite by means of an amide bond and in that at least one of said grafts comprises at least one oligoamino acid which is Leu, and/or Ileu, and/or Val, and/or Phe based. Said amide function ensure better stability with respect to hydrolysis than similar products of prior art. Advantageously, said polymers can be easily and economically transformed into active substance vectorization particles, said particles being able to form stable aqueous colloidal suspensions.
    Type: Application
    Filed: November 20, 2006
    Publication date: August 2, 2007
    Applicant: Flamel Technologies
    Inventors: Stephanie Angot, You-Ping Chan, Gerard Soula
  • Publication number: 20070173464
    Abstract: The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C virus by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of patients. Said composition comprises at least one modified release form of ribavirin, the bio-absorption time BAT of which is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 h and more preferably between 4 and 12 h. Said composition is a reservoir type form or a matrix type form.
    Type: Application
    Filed: February 16, 2007
    Publication date: July 26, 2007
    Applicant: Flamel Technologies
    Inventors: Florence Guimberteau, Catherine Castan, Remi Meyrueix, Gerard Soula
  • Publication number: 20070166378
    Abstract: The invention relates to oral pharmaceutical compositions for the prevention and/or the treatment of viral diseases. This invention also addresses methods of prevention and/or treatment of these viral diseases, using these oral compositions. One of the main problems considered in the present invention is to enhance the efficiency of anti-viral treatments, especially against Hepatitis C virus by means of ribavirin, for example in combination with interferon. The oral ribavirin antiviral composition according to the invention increases the bio-absorption time of ribavirin, and thus improves the treatment of patients. Said composition comprises at least one modified release form of ribavirin, the bio-absorption time BAT of which is greater than the bio-absorption time BAT* of a reference* immediate release form of ribavirin administered at the same dose; BAT being preferably comprised between 2 and 15 h and more preferably between 4 and 12 h. Said composition is a reservoir type form or a matrix type form.
    Type: Application
    Filed: June 9, 2006
    Publication date: July 19, 2007
    Applicant: Flamel Technologies, Inc.
    Inventors: Florence Guimberteau, Catherine Castan, Remi Meyrueix, Gerard Soula
  • Publication number: 20070160568
    Abstract: The invention relates to novel materials based on biodegradable polyamino acids that are useful for vectorizing active principle/s (AP). The aim of the invention is to supply a new polymeric raw material that is used for vectorizing AP and optimally fulfills all requirements concerning biocompatibility, biodegradability, the ability to be easily associated with numerous active principles or solubilize said active principles and to release the active principles in vivo. Said polymers can also be readily and economically transformed into particles vectorizing active principles according to the grafting rate of the hydrophobic groups, said particles being able to form stable aqueous colloidal suspensions.
    Type: Application
    Filed: August 25, 2006
    Publication date: July 12, 2007
    Applicant: Flamel Technologies, Inc.
    Inventors: Stephanie Angot, Olivier Breyne, You-Ping Chan, Gerard Soula
  • Patent number: 7226618
    Abstract: A suspension of vector particles (PV) based on polyamino acids and have a mean hydrodynamic diameter between 30 and 120 nm, and an insulin load factor of from 5 to 25% of associated insulin volume relative to the polyamino acid volume forming the vector particles. The polyamino acids are double-block polymers containing hydrophilic and hydrophobic monomers. The suspension may be prepared by copolymerizing N-carboxy anhydrides of hydrophobic monomers and precursors of hydrophilic monomers, in the presence of N-methyl pyrrolidone and methanol. The copolymer is optionally neutralized, subjected to dialysis, concentrated and water is eliminated to produce a solid powder, which can be suspended in a liquid to produce the colloidal suspension. Active principles such as insulin or vaccines are associated with the carrier particles to prepare special pharmaceutical products.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: June 5, 2007
    Assignee: Flamel Technologies, Inc.
    Inventors: Franck Touraud, Nathan Bryson
  • Publication number: 20050196459
    Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.
    Type: Application
    Filed: November 24, 2004
    Publication date: September 8, 2005
    Applicant: Flamel Technologies S.A.
    Inventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula
  • Patent number: 6916909
    Abstract: The invention relates to novel collagen peptides that are modified by grafting free or substitued thiol functions carried by mercaptoamine radicals. The aim of the invention is to provide thiol collagens that can be cross-linked in a sufficient and controlled manner by forming S—S bridges and which are biocompatible. This is achieved by means of the inventive thiol collagens which are characterized in that the mercaptoamine radicals are identical to or different from each other and are exclusively grafted on the aspartic and glutamic acids of the collagen chain by amide bonds. The invention also relates to a method for the production of said thiol and cross-linkable collagens. The novel modified cross-linkable and/or cross-linked collagens can be used as biomaterials.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: July 12, 2005
    Assignee: Flamel Technologies
    Inventors: Florence Nicolas, Nathan Bryson